The American journal of medicine
-
Some patients are at higher risk for recurrent cardiovascular events following a myocardial infarction because of their clinical characteristics and comorbidities. Still, they are less often treated with guideline-recommended therapies. We examined trends for more than a decade in the treatment and outcome of patients with myocardial infarction according to the risk for recurrent cardiovascular events, using the Thrombolysis in Myocardial Infarction (TIMI) risk score for secondary prevention. ⋯ Despite greater application of guideline-recommended therapies, patients at high risk after myocardial infarction are still relatively undertreated, which may adversely affect their prognosis. Nevertheless, they demonstrated the most notable improvement in clinical outcomes over time.
-
For decades, omega-3 fatty acids (O3FA) have been used for their cardioprotective effects. Although several prescription products are available, icosapent ethyl (IPE) is the lone pure, eicosapentaenoic acid (EPA)-only, O3FA product. ⋯ Based on the REDUCE-IT trial, the Food and Drug Administration granted IPE an indication for ASCVD risk reduction, making it the first O3FA product to receive such an indication. IPE is a cost-effective approach to reducing residual cardiovascular risk in high risk patients treated with statins.